South Korea · Delayed Price · Currency is KRW Mezzion Pharma Statistics
Total Valuation
Mezzion Pharma has a market cap or net worth of KRW 2.26 trillion. The enterprise value is 2.24 trillion.
| Market Cap | 2.26T |
| Enterprise Value | 2.24T |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mezzion Pharma has 30.61 million shares outstanding. The number of shares has increased by 1.36% in one year.
| Current Share Class | 30.61M |
| Shares Outstanding | 30.61M |
| Shares Change (YoY) | +1.36% |
| Shares Change (QoQ) | +1.98% |
| Owned by Insiders (%) | 9.18% |
| Owned by Institutions (%) | 4.87% |
| Float | 22.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 268.71 |
| PB Ratio | 58.01 |
| P/TBV Ratio | 60.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 265.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68, with a Debt / Equity ratio of 0.44.
| Current Ratio | 0.68 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.84 |
| Interest Coverage | -5.89 |
Financial Efficiency
Return on equity (ROE) is -68.29% and return on invested capital (ROIC) is -142.13%.
| Return on Equity (ROE) | -68.29% |
| Return on Assets (ROA) | -11.01% |
| Return on Invested Capital (ROIC) | -142.13% |
| Return on Capital Employed (ROCE) | -47.05% |
| Weighted Average Cost of Capital (WACC) | 10.41% |
| Revenue Per Employee | 468.25M |
| Profits Per Employee | -1.52B |
| Employee Count | 18 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -1.95B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.62% in the last 52 weeks. The beta is 1.11, so Mezzion Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +32.62% |
| 50-Day Moving Average | 60,508.00 |
| 200-Day Moving Average | 85,349.50 |
| Relative Strength Index (RSI) | 65.58 |
| Average Volume (20 Days) | 83,491 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mezzion Pharma had revenue of KRW 8.43 billion and -27.39 billion in losses. Loss per share was -902.06.
| Revenue | 8.43B |
| Gross Profit | 1.43B |
| Operating Income | -18.88B |
| Pretax Income | -29.34B |
| Net Income | -27.39B |
| EBITDA | -18.00B |
| EBIT | -18.88B |
| Loss Per Share | -902.06 |
Balance Sheet
The company has 40.31 billion in cash and 17.32 billion in debt, with a net cash position of 22.99 billion or 751.23 per share.
| Cash & Cash Equivalents | 40.31B |
| Total Debt | 17.32B |
| Net Cash | 22.99B |
| Net Cash Per Share | 751.23 |
| Equity (Book Value) | 39.04B |
| Book Value Per Share | 1,285.33 |
| Working Capital | -27.06B |
Cash Flow
In the last 12 months, operating cash flow was -20.49 billion and capital expenditures -60.82 million, giving a free cash flow of -20.55 billion.
| Operating Cash Flow | -20.49B |
| Capital Expenditures | -60.82M |
| Depreciation & Amortization | 882.91M |
| Net Borrowing | 30.95B |
| Free Cash Flow | -20.55B |
| FCF Per Share | -671.44 |
Margins
| Gross Margin | 17.02% |
| Operating Margin | -223.98% |
| Pretax Margin | -348.14% |
| Profit Margin | n/a |
| EBITDA Margin | -213.50% |
| EBIT Margin | -223.98% |
| FCF Margin | n/a |
Dividends & Yields
Mezzion Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.36% |
| Shareholder Yield | -1.36% |
| Earnings Yield | -1.21% |
| FCF Yield | -0.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Apr 5, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Mezzion Pharma has an Altman Z-Score of 13.63 and a Piotroski F-Score of 1.
| Altman Z-Score | 13.63 |
| Piotroski F-Score | 1 |